

Heinz Regele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8583874/publications.pdf>

Version: 2024-02-01

53
papers

2,050
citations

361413

20
h-index

243625

44
g-index

90
all docs

90
docs citations

90
times ranked

2266
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term results of autologous scaffold-free tissue-engineered vascular graft for hemodialysis access. <i>Journal of Vascular Access</i> , 2024, 25, 254-264.	0.9	10
2	Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. <i>Trials</i> , 2022, 23, 270.	1.6	8
3	Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection. <i>Frontiers in Medicine</i> , 2022, 9, 817127.	2.6	2
4	Proteinuria in Deceased Kidney Transplant Donors for Prediction of Chronic Lesions in Pretransplant Biopsies: A Prospective Observational Study. <i>Transplantation</i> , 2022, Publish Ahead of Print, .	1.0	2
5	Ex vivo fluorescence confocal microscopy: chances and changes in the analysis of breast tissue. <i>Diagnostic Pathology</i> , 2022, 17, .	2.0	3
6	Distinct roles for major and minor antigen barriers in chimerism-based tolerance under irradiation-free conditions. <i>American Journal of Transplantation</i> , 2021, 21, 968-977.	4.7	5
7	A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 708-722.	6.1	101
8	Renal allograft DARCness in subclinical acute and chronic active ABMR. <i>Transplant International</i> , 2021, 34, 1494-1505.	1.6	3
9	In vivo Treg expansion under costimulation blockade targets early rejection and improves long-term outcome. <i>American Journal of Transplantation</i> , 2021, 21, 3765-3774.	4.7	10
10	Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients. <i>Transplant International</i> , 2021, 34, 1689-1702.	1.6	16
11	Torque Teno Virus Load Is Associated With Subclinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial. <i>Transplantation</i> , 2021, 105, 2112-2118.	1.0	29
12	Prospective Tracking of Donor-Reactive T-Cell Clones in the Circulation and Rejecting Human Kidney Allografts. <i>Frontiers in Immunology</i> , 2021, 12, 750005.	4.8	20
13	Clinical Relevance of Absolute BK Polyoma Viral Load Kinetics in Patients With Biopsy Proven BK Polyomavirus Associated Nephropathy. <i>Frontiers in Medicine</i> , 2021, 8, 791087.	2.6	0
14	Lymphangiogenesis in a mouse model of renal transplant rejection extends life span of the recipients. <i>Kidney International</i> , 2020, 97, 89-94.	5.2	22
15	Tubular Ectasia in Renal Allograft Biopsy: Associations With Occult Obstructive Urological Complications. <i>Transplantation</i> , 2020, 104, 145-153.	1.0	1
16	Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: Prospects for molecular diagnosis and risk prediction. <i>American Journal of Transplantation</i> , 2020, 20, 3486-3501.	4.7	19
17	Immunoadsorption Combined with Membrane Filtration to Counteract Early Treatment-Refractory Antibody-Mediated Rejection. <i>Blood Purification</i> , 2020, 49, 576-585.	1.8	5
18	Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. <i>Frontiers in Medicine</i> , 2020, 7, 114.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Magnetic Resonance Imaging for Evaluation of Interstitial Fibrosis in Kidney Allografts. <i>Transplantation Direct</i> , 2020, 6, e577.	1.6	12
20	Allograft and patient survival after sequential HSCT and kidney transplantation from the same donorâ€”A multicenter analysis. <i>American Journal of Transplantation</i> , 2019, 19, 475-487.	4.7	14
21	Allograft rejection is associated with development of functional IgE specific for donor MHC antigens. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 335-345.e12.	2.9	18
22	Natural Killer Cells Promote Kidney Graft Rejection Independently of Cyclosporine A Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 2279.	4.8	13
23	FP100HISTOLOGICAL FEATURES IN THE RENAL ALLOGRAFT PREDICTING OCCULT UROLOGICAL OBSTRUCTIVE COMPLICATIONS IN THE EARLY POST-TRANSPLANTATION PHASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
24	Next generation sequencing based assessment of the alloreactive T cell receptor repertoire in kidney transplant patients during rejection: a prospective cohort study. <i>BMC Nephrology</i> , 2019, 20, 346.	1.8	13
25	Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. <i>Trials</i> , 2019, 20, 37.	1.6	48
26	Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review. <i>European Urology Focus</i> , 2019, 5, 508-517.	3.1	14
27	Blockade of adhesion molecule lymphocyte functionâ€”associated antigen-1 improves long-term heart allograft survival in mixed chimeras. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1119-1130.	0.6	2
28	A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 591-605.	6.1	220
29	The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 94-108.	1.9	46
30	Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel. <i>European Urology Focus</i> , 2018, 4, 153-162.	3.1	24
31	European Association of Urology Guidelines on Renal Transplantation: Update 2018. <i>European Urology Focus</i> , 2018, 4, 208-215.	3.1	85
32	Lymphotoxin expression in human and murine renal allografts. <i>PLoS ONE</i> , 2018, 13, e0189396.	2.5	6
33	Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejectionâ€”Results of a Cross-Sectional Screening Study. <i>Transplantation</i> , 2017, 101, 631-641.	1.0	60
34	Disturbances in iron homeostasis result in accelerated rejection after experimental heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 732-743.	0.6	16
35	miR-182-5p Inhibition Ameliorates Ischemic Acute Kidney Injury. <i>American Journal of Pathology</i> , 2017, 187, 70-79.	3.8	52
36	Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model. <i>Frontiers in Immunology</i> , 2017, 8, 821.	4.8	14

#	ARTICLE	IF	CITATIONS
37	MELAS Syndrome and Kidney Disease Without Fanconi Syndrome or Proteinuria: A Case Report. American Journal of Kidney Diseases, 2016, 68, 949-953.	1.9	13
38	Renal microRNA and miRNA profiles in progressive chronic kidney disease. European Journal of Clinical Investigation, 2016, 46, 213-226.	3.4	96
39	The lymphotoxin $\hat{1}^2$ receptor is a potential therapeutic target in renal inflammation. Kidney International, 2016, 89, 113-126.	5.2	16
40	Detection of alloantibody-mediated complement activation: A diagnostic advance in monitoring kidney transplant rejection?. Clinical Biochemistry, 2016, 49, 394-403.	1.9	22
41	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. Oncotarget, 2016, 7, 12191-12205.	1.8	6
42	Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1435-1443.	4.5	41
43	The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. Kidney International, 2015, 88, 332-340.	5.2	27
44	Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials, 2014, 15, 107.	1.6	41
45	The cutting (w)edge-comparative evaluation of renal baseline biopsies obtained by two different methods. Nephrology Dialysis Transplantation, 2012, 27, 3241-3248.	0.7	18
46	Non-HLA antibodies in kidney allograft rejection: convincing concept in need of further evidence. Kidney International, 2011, 79, 583-586.	5.2	18
47	Diagnosis and treatment of antibody-mediated kidney allograft rejection. Transplant International, 2003, 16, 773-787.	1.6	27
48	When renal allografts turn darcl. Transplantation, 2003, 75, 1030-1034.	1.0	41
49	Capillary Deposition of Complement Split Product C4d in Renal Allografts is Associated with Basement Membrane Injury in Peritubular and Glomerular Capillaries. Journal of the American Society of Nephrology: JASN, 2002, 13, 2371-2380.	6.1	394
50	C4d-Positive Acute Humoral Renal Allograft Rejection. Journal of the American Society of Nephrology: JASN, 2001, 12, 2482-2489.	6.1	128
51	The Duffy antigen receptor for chemokines is up-regulated during acute renal transplant rejection and crescentic glomerulonephritis. Kidney International, 2000, 58, 1546-1556.	5.2	81
52	Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients. Transplant International, 2000, 13, 187-193.	1.6	4
53	The Original Gerstmann-Str�ussler-Scheinker Family of Austria: Divergent Clinicopathological Phenotypes but Constant PrP Genotype. Brain Pathology, 1995, 5, 201-211.	4.1	141